Johnson & Johnson is acquiring the remaining stake in Verb Surgical Inc. from Verily, Alphabet Inc.’s life sciences division.

The first comprehensive study comparing the outcomes of robotic surgery to those of traditional open surgery in any organ found that the surgeries are equally effective in treating bladder cancer.

EGP-437 demonstrated better clinical performance than vehicle control, but did not meet its co-primary endpoints.

An FDA advisory committee voted 6 in favor and 6 against the benefit-risk profile for Pfizer’s Sutent as adjuvant treatment of adults at high risk of recurrent RCC after nephrectomy.

The world’s top medical technology companies are turning to robots to help with complex knee surgery, promising quicker procedures and better results in operations that often leave patients dissatisfied.

Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis in a new $300 million fund run by leading life sciences investment firm Medicxi.

Kala Pharmaceuticals Inc. today announced positive top-line results from its confirmatory Phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery.

A thirty-something year old blind woman has her sight restored and sees her young baby for the first time; a 6-year-old boy regains his sight, and for the first time in his life, he sees the face of his parents.

Johnson & Johnson announced it will acquire Abbott Medical Optics for more than $4 billion. The deal is expected to close in the first quarter of 2017.

Only days after Google’s Life Sciences spinoff announced its new name, Verily Life Sciences, Johnson & Johnson (JNJ) announced a collaboration with Verily to create an independent surgical solutions company, Verb Surgical Inc. In March 2015, JNJ’s Ethicon, Inc. (JNJ), a medical devices company, announced a strategic collaboration with Google Life Sciences. The focus of […]